Skip to main content
SpringerLink
Log in

Afatinib/crizotinib/erlotinib

Various toxicities: 2 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Singh PK, et al. Unearthing EGFR mutations and the rewards of persistence in precision oncology: Breaching the 10-year survival barrier in metastatic NSCLC with active disease. Journal of Global Oncology 2020: 174-179, No. 6, 31 Jan 2020. Available from: URL: http://doi.org/10.1200/JGO.19.00357

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Afatinib/crizotinib/erlotinib. Reactions Weekly 1796, 18 (2020). https://doi.org/10.1007/s40278-020-76305-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-76305-1

Search

Navigation